Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical
Retrieved on:
Wednesday, February 15, 2023
Macroglobulinemia, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Pleasure, Pfizer, Internal medicine, Orientation, Division, Patient, University, Research, Senior, Merck, WellSpan Health, Compensated emancipation, Bristol Myers Squibb, Faculty, Simferopol, Employment, AstraZeneca, Cancer, Pharmaceutical industry, Seagen, Hematology, Medicine
In this role, Dr. Shustov will lead and provide oversight on all aspects of the Company’s clinical development program, medical affairs, and medical communications.
Key Points:
- In this role, Dr. Shustov will lead and provide oversight on all aspects of the Company’s clinical development program, medical affairs, and medical communications.
- “It is a pleasure for me to welcome Andrei to the Cellectar team,” said James Caruso, president, and CEO of Cellectar.
- “His strong business orientation, excellent cultural alignment and extensive hematology experience makes him our ideal medical lead.
- The grant was made as an inducement material for Dr. Shustov’s employment with Cellectar as contemplated by Nasdaq Listing Rule 5635(c)(4).